4:48 PM
 | 
Dec 27, 2012
 |  BC Extra  |  Company News

Teva returning preclinical compounds to Proteologics

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said it will return rights to three preclinical compounds in development for cancer and inflammation to Proteologics Inc. (Tel Aviv:PRTL), effective Jan. 5, 2013. Teva said the decision to return the compounds is...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >